Salvage therapy of imatinib-resistant hypereosinophilic syndrome with PDGFRB rearrangement
Hypereosinophilic syndrome (HES) has generally been defined as a peripheral blood eosinophil count greater than 1500/mm3 and may be associated with tissue damage. Imatinib is customarily used as the first-line therapy for HES with gene abnormalities, such as PDGFRA or PDGFRB. We presented a case whe...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-03-01
|
Series: | Journal of Cancer Research and Practice |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S231130061500004X |